Story
Hims & Hers Stock Slides on Wider-Than-Expected Q2 Loss

Shares of Hims & Hers Health Inc. (NYSE: HIMS) declined more than 7% in pre-market trading after the telehealth company reported a second-quarter loss that was substantially wider than Wall Street forecasts. The significant earnings miss overshadowed strong revenue growth and a raised annual outlook, sparking investor concerns over the company's path to sustained profitability.
Earnings Report Disappoints
In its Q2 2026 results released after Monday's close, Hims & Hers disclosed a mixed performance that ultimately failed to reassure investors. While revenue impressed, the bottom line fell far short of expectations.
Key figures from the report include:
- Loss Per Share: A net loss of $0.37, which was significantly larger than the consensus analyst forecast for a loss of just $0.05.
- Revenue: Approximately $753 million, representing a 38% increase year-over-year and beating consensus estimates by nearly 9%.
- Q3 Guidance: The company's forecast for third-quarter adjusted EBITDA came in below Wall Street's expectations.
The combination of a steep earnings miss and a cautious near-term profitability outlook appeared to be the primary drivers of the negative investor reaction.
Margin Pressure and Cash Flow Concerns
AdThe wider-than-expected loss was primarily attributed to significant pressure on the company's gross margins, which fell to approximately 64%. According to the report, this compression stems from the company's strategic shift away from compounded GLP-1 medications toward more expensive branded weight-loss drugs. The transition resulted in $4.6 million in restructuring charges during the quarter.
Adding to the concerns, free cash flow remained deeply negative at around -$68 million. This figure highlights the cash burn associated with the company's current strategy, further worrying investors focused on the company's financial stability.
Outlook and Market Context
Despite the quarterly loss, management expressed confidence in its top-line growth by raising its full-year 2026 revenue guidance to a new range of $3.1 billion to $3.3 billion. However, this positive development was not enough to offset the immediate concerns about profitability.
An existing Federal Trade Commission (FTC) lawsuit, which alleges the company shared sensitive user health data with third-party advertisers, also remains a legal overhang for the stock. With the broader U.S. stock market trading nearly flat, the sharp drop in Hims & Hers shares was driven almost entirely by these company-specific factors.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.